Clinical Trials in the USA / NCT05573984
Active, not recruiting
Observational
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
NCT05573984 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Retinitis PigmentosaEye Diseases, HereditaryRetinal DystrophiesRetinal Dystrophy RodRetinal Dystrophy Rod Progressive
Study summary
The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11.
Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.
Eligibility
Inclusion Criteria:
Participants must meet all of the following in order to be enrolled into the study:
1. Male or female, ≥ 10 years of age at baseline (Visit 2).
2. Have a clinical and molecular diagnosis of PRPF31 mutation-associated retinal dystrophy.
3. If ≥ 18 years of age, understand the language of the informed consent and are willing and able to provide written informed consent prior to any study procedures. If \< 18 years of age, are willing to assent to study participation in writing and have a legally authorized representative provide written informed consent on your behalf.
4. Are willing to comply with the instructions and attend all scheduled study visits.
Exclusion Criteria:
Participants or, in the case of ocular-specific criteria, individual eyes with any of the following will not be allowed to participate in this study:
1. Have any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study (e.g., infection, uncontrolled elevated blood pressure, cardiovascular disease, or glycemic control issues) or put the participant at risk due to study procedures.
2. Have mutations in genes that cause autosomal dominant retinitis pigmentosa (adRP), X-linked retinitis pigmentosa (XLRP), or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than PRPF31 mutations.
3. Have used anti-vascular endothelial growth factor (VEGF) agents or corticosteroid injections or implants.
4. Have had Ozurdex® implants placed within 3 months or Retisert® or Iluvien® implants placed within 3 years prior to Visit 2.
5. Within 3 months prior to Visit 2, have undergone any vitreoretinal surgery (scleral buckle, pars plana vitrectomy, retrieval of a dropped nucleus or intraocular lens, radial optic neurotomy, sheathotomy, cyclodestructive procedures or multiple filtration surgeries \[2 or more\], etc.) or any other ocular surgery.
6. Have ocular media opacity or poor pupillary dilation that prohibits quality ophthalmic evaluation or photography.
7. Have used any investigational drug or device within 90 days or 5 estimated half-lives of Visit 2, whichever is longer, or plan to participate in another study of drug or device during the study period.
8. Have received any prior cell or gene therapy for a retinal condition.
9. Have a history of illicit drug use or alcohol dependency.
Primary outcome measure(s)
- Change from Baseline in Best Corrected Visual Acuity (BCVA) — Baseline through Year 4
BCVA letter score utilizing ETDRS (Early Treatment Diabetic Retinopathy Study) or BRVT (Berkeley Rudimentary Vision Test) for patients not able to see letters - Change in Best Corrected Low Luminance Visual Acuity (LLVA) — Baseline through Year 4
Best corrected LLVA letter score measured using the ETDRS charts and a special light filter lens - Change from Baseline in Retinal Thickness — Baseline through Year 4
Retinal thickness is measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center - Change from Baseline in Ellipsoid Zone (EZ) Area — Baseline through Year 4
Change in EZ area measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center - Change from Baseline in Ellipsoid Zone (EZ) Volume — Baseline through Year 4
Change in EZ volume measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center - Change from Baseline in Visual Field Sensitivity — Baseline through Year 4
Visual field sensitivity measured by static perimetry with topographic analysis-Hill of Vision conducted by the central reading center - Change from Baseline in Mean Macular Sensitivity — Baseline through Year 4
Mean macular sensitivity measured on guided microperimetry - Change from Baseline in Fixation Stability — Baseline through Year 4
Fixation stability as measured by Macular Integrity Assessment (MAIA) microperimeter - Change from Baseline in Full Field Retinal Sensitivity — Baseline through Year 4
Dark-adapted visual sensitivity via full-field stimulus threshold (FST) measurement - Change from Baseline in Electrical response — Baseline through Year 4
Electrical response measured using Full-field electroretinogram (ERG) with specific stimuli - Characterization of Changes of the Retina with Fundus Photography — Baseline through Year 4
Abnormalities captured by fundus photography - Change from Baseline in Area of Fundus Autofluorescence (FAF) — Baseline through Year 4
Area of hypo-autofluorescence captured by fundus autofluorescence (FAF) - Change from Baseline in Functional Vision — 3 times prior to Month 4
Functional vision is measured with a functional mobility course (Ora-VNC™) score - Change in Patient Reported Outcome Measures using Michigan Retinal Degeneration Questionnaire (MRDQ) — Baseline through Year 4
Responses on the MRDQ, a validated patient reported outcomes measure designed in accordance with U.S. FDA guidelines, specifically for conditions of inherited retinal degeneration (IRDs) - Change in Patient Reported Outcome Measures using Patient Global Impression of Severity (PGI-S) scale — Baseline through Year 4
Responses on the PGI-S to assess severity of the patient's condition - Change in Patient Reported Outcome Measures using Patient Global Impression of Change (PGI-C) scale — Baseline through Year 4
Responses on the PGI-C to assess change of the patient's condition - Genomic Analysis for Study Eligibility — Screening
Whole exome genomic analysis - Ocular Adverse Events (AEs) — Screening through Year 4
Frequency of ocular adverse events (AEs)
Trial sites (7)
| Facility | City | Region | Status |
|---|---|---|---|
| University of California San Francisco | San Francisco | California | |
| University of Florida Health | Jacksonville | Florida | |
| University of Michigan Kellogg Eye Center | Ann Arbor | Michigan | |
| Oregon Health and Science University - Casey Eye Institute | Portland | Oregon | |
| Retina Foundation of the Southwest | Dallas | Texas | |
| Lions Eye Institute | Nedlands | Western Australia | |
| Centre For Eye Research Australia (CERA) - Retinal Gene Therapy Unit | East Melbourne | Australia |
More PYC Therapeutics trials in the USA
Other trials for the same condition
A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)
Active, not recruiting
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Active, not recruiting
Prospective Natural History Study of Retinitis Pigmentosa
Active, not recruiting
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05573984 on ClinicalTrials.gov ↗ ← All trials in the USA